Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Atea Pharmaceuticals (AVIR) Shares Outstanding (Weighted Average) (2019 - 2026)

Atea Pharmaceuticals' Shares Outstanding (Weighted Average) history spans 8 years, with the latest figure at $79.2 million for Q1 2026.

  • Quarterly Shares Outstanding (Weighted Average) fell 7.0% to $79.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $79.2 million through Mar 2026, down 7.0% year-over-year, with the annual reading at $81.5 million for FY2025, 3.29% down from the prior year.
  • Shares Outstanding (Weighted Average) came in at $79.2 million for Q1 2026, down from $81.5 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $85.2 million in Q1 2025 to a low of $79.1 million in Q3 2025.
  • The 5-year median for Shares Outstanding (Weighted Average) is $83.4 million (2023), against an average of $83.0 million.
  • Year-over-year, Shares Outstanding (Weighted Average) increased 1.48% in 2025 and then fell 7.0% in 2026.
  • Atea Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $83.2 million in 2022, then rose by 0.17% to $83.4 million in 2023, then grew by 1.05% to $84.3 million in 2024, then dropped by 3.29% to $81.5 million in 2025, then fell by 2.82% to $79.2 million in 2026.
  • Per Business Quant, the three most recent readings for AVIR's Shares Outstanding (Weighted Average) are $79.2 million (Q1 2026), $81.5 million (Q4 2025), and $79.1 million (Q3 2025).